<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ep-patent-document PUBLIC "-//EPO//EP PATENT DOCUMENT 1.5//EN" "ep-patent-document-v1-5.dtd">
<ep-patent-document id="EP16708853B8W1" file="EP16708853W1B8.xml" lang="en" country="EP" doc-number="3261658" kind="B8" correction-code="W1" date-publ="20190605" status="c" dtd-version="ep-patent-document-v1-5">
<SDOBI lang="en"><B000><eptags><B001EP>ATBECHDEDKESFRGBGRITLILUNLSEMCPTIESILTLVFIROMKCYALTRBGCZEEHUPLSKBAHRIS..MTNORSMESM..................</B001EP><B003EP>*</B003EP><B005EP>J</B005EP><B007EP>BDM Ver 0.1.63 (23 May 2017) -  2999001/0</B007EP></eptags></B000><B100><B110>3261658</B110><B120><B121>CORRECTED EUROPEAN PATENT SPECIFICATION</B121></B120><B130>B8</B130><B132EP>B1</B132EP><B140><date>20190605</date></B140><B150><B151>W1</B151><B153>73</B153><B155><B1551>de</B1551><B1552>Bibliographie</B1552><B1551>en</B1551><B1552>Bibliography</B1552><B1551>fr</B1551><B1552>Bibliographie</B1552></B155></B150><B190>EP</B190></B100><B200><B210>16708853.3</B210><B220><date>20160218</date></B220><B240><B241><date>20170905</date></B241></B240><B250>en</B250><B251EP>en</B251EP><B260>en</B260></B200><B300><B310>201562119592 P</B310><B320><date>20150223</date></B320><B330><ctry>US</ctry></B330></B300><B400><B405><date>20190605</date><bnum>201923</bnum></B405><B430><date>20180103</date><bnum>201801</bnum></B430><B450><date>20190403</date><bnum>201914</bnum></B450><B452EP><date>20190221</date></B452EP><B480><date>20190605</date><bnum>201923</bnum></B480></B400><B500><B510EP><classification-ipcr sequence="1"><text>A61K  38/12        20060101AFI20170906BHEP        </text></classification-ipcr><classification-ipcr sequence="2"><text>A61P  31/00        20060101ALI20170906BHEP        </text></classification-ipcr></B510EP><B540><B541>de</B541><B542>DOSEN UND VERFAHREN ZUR VERABREICHUNG VON TELAVANCIN</B542><B541>en</B541><B542>DOSES AND METHODS OF ADMINISTERING TELAVANCIN</B542><B541>fr</B541><B542>DOSES ET PROCÉDÉS D'ADMINISTRATION DE TÉLAVANCINE</B542></B540><B560><B561><text>WO-A2-2005/042568</text></B561><B562><text>G. R. COREY ET AL: "Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 58, no. 4, 1 April 2014 (2014-04-01), pages 2030-2037, XP055271375, US ISSN: 0066-4804, DOI: 10.1128/AAC.02330-13</text></B562><B562><text>T. P. LODISE ET AL: "Telavancin Pharmacokinetics and Pharmacodynamics in Patients with Complicated Skin and Skin Structure Infections and Various Degrees of Renal Function", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, vol. 56, no. 4, 1 April 2012 (2012-04-01), pages 2062-2066, XP055271388, US ISSN: 0066-4804, DOI: 10.1128/AAC.00383-11</text></B562><B562><text>ETHAN RUBINSTEIN ET AL: "Telavancin for the treatment of serious gram-positive infections, including hospital acquired pneumonia", EXPERT OPINION ON PHARMACOTHERAPY, vol. 12, no. 17, 15 December 2011 (2011-12-15), pages 2737-2750, XP055271400, LONDON, UK ISSN: 1465-6566, DOI: 10.1517/14656566.2011.633511</text></B562><B562><text>M. P. PAI: "Comment on: Acute renal insufficiency during telavancin therapy in clinical practice", JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY., vol. 67, no. 5, 13 February 2012 (2012-02-13), pages 1300-1301, XP055271518, GB ISSN: 0305-7453, DOI: 10.1093/jac/dks029</text></B562><B562><text>SAMUEL ERIC WILSON ET AL: "Telavancin, a new lipoglycopeptide antimicrobial, in complicated skin and soft tissue infections", INFECTION AND DRUG RESISTANCE, 1 March 2011 (2011-03-01), page 87, XP055293510, DOI: 10.2147/IDR.S5327</text></B562></B560></B500><B700><B720><B721><snm>BARRIERE, Steven L.</snm><adr><str>1660 Lyon Street</str><city>San Francisco, California 94115</city><ctry>US</ctry></adr></B721><B721><snm>LO, Arthur</snm><adr><str>1485 46th Avenue</str><city>San Francisco, California 94122</city><ctry>US</ctry></adr></B721><B721><snm>MAMMEN, Mathai</snm><adr><str>1852 Valparaiso Avenue</str><city>Menlo Park, California 94025</city><ctry>US</ctry></adr></B721><B721><snm>WORBOYS, Philip</snm><adr><str>30 Chester Way</str><city>San Mateo, California 94402</city><ctry>US</ctry></adr></B721></B720><B730><B731><snm>Cumberland Pharmaceuticals Inc.</snm><iid>101226947</iid><irf>P122036EP-WO</irf><adr><str>2525 West End Avenue 
Suite 950</str><city>Nashville, TN 37203</city><ctry>US</ctry></adr></B731></B730><B740><B741><snm>Bassil, Nicholas Charles</snm><iid>100044891</iid><adr><str>Kilburn &amp; Strode LLP 
Lacon London 
84 Theobalds Road</str><city>London WC1X 8NL</city><ctry>GB</ctry></adr></B741></B740></B700><B800><B840><ctry>AL</ctry><ctry>AT</ctry><ctry>BE</ctry><ctry>BG</ctry><ctry>CH</ctry><ctry>CY</ctry><ctry>CZ</ctry><ctry>DE</ctry><ctry>DK</ctry><ctry>EE</ctry><ctry>ES</ctry><ctry>FI</ctry><ctry>FR</ctry><ctry>GB</ctry><ctry>GR</ctry><ctry>HR</ctry><ctry>HU</ctry><ctry>IE</ctry><ctry>IS</ctry><ctry>IT</ctry><ctry>LI</ctry><ctry>LT</ctry><ctry>LU</ctry><ctry>LV</ctry><ctry>MC</ctry><ctry>MK</ctry><ctry>MT</ctry><ctry>NL</ctry><ctry>NO</ctry><ctry>PL</ctry><ctry>PT</ctry><ctry>RO</ctry><ctry>RS</ctry><ctry>SE</ctry><ctry>SI</ctry><ctry>SK</ctry><ctry>SM</ctry><ctry>TR</ctry></B840><B844EP><B845EP><ctry>BA</ctry><date>20170905</date></B845EP><B845EP><ctry>ME</ctry><date>20170905</date></B845EP></B844EP><B860><B861><dnum><anum>US2016018396</anum></dnum><date>20160218</date></B861><B862>en</B862></B860><B870><B871><dnum><pnum>WO2016137806</pnum></dnum><date>20160901</date><bnum>201635</bnum></B871></B870></B800></SDOBI>
</ep-patent-document>
